Table 4. Analysis of relative β-catenin N/M/C (nuclear, membranous/cytoplasmic) frequency in paediatric and adult mesenchymal tumours.
| Paediatric mesenchymal tumours | No. cases | N β-catenin (>50%)* | N β-catenin (>25%)* | M/C β-catenin (≥50%) |
|---|---|---|---|---|
| Nodular fasciitis | 7 | 1/7 | 1/7 | 7/7 |
| (14%) | (14%) | (100%) | ||
| Myofibroma/Dermatomyofibroma/Myofibromatosis | 8 | 2/8 | 1/8 | 4/8 |
| (25%) | (12.5%) | (50%) | ||
| Fibromatosis, adult-type | 5 | 5/5 | 3/5 | 5/5 |
| 100% | 60% | (100%) | ||
| Fibromatosis, infantile-type | 4 | 1/4 | 0/4 | 3/4 |
| (25%) | (0) | (75%) | ||
| Lipofibromatosis | 2 | 0/2 | 0/2 | 0/2 |
| (0) | (0) | (0) | ||
| Myxoma | 1 | 0/1 | 0/1 | 1/1 |
| (0) | (0) | (100%) | ||
| Keloid/Hypertrophic scar | 8 | 2/8 | 1/8 | 5/8 |
| (25%) | (12.5%) | (62.5%) | ||
| Fibrosarcoma | 4 | 1/4 | 1/4 | 3/4 |
| (25%) | (25%) | (75%) | ||
| Rhabdo/leiomyosarcoma | 2 | 0/2 | 0/2 | 2/2 |
| (0) | (0) | (100%) |
| Adult mesenchymal tumours | No. cases | N β-catenin (>25%) | N β-catenin (>5%) | M/C β-catenin (≥50%) |
|---|---|---|---|---|
| Angiosarcoma | 4 | 0/4 | 0/4 | 2/4 |
| (0%) | (0%) | (50%) | ||
| Liposarcoma | 6 | 1/6 | 1/6 | 4/6 |
| (16%) | (16%) | (66.6%) | ||
| Sarcoma (clear cell and synovial) | 2 | 0/2 | 0/2 | 2/2 |
| (0) | (0) | (100%) | ||
| Fibrosarcoma | 6 | 0/6 | 1/6 | 5/6 |
| (0%) | (16.6%) | (83.3%) | ||
| Leiomyosarcoma/Rhabdomyosarcoma | 6 | 0/6 | 1/6 | 5/6 |
| (0%) | (16%) | (83.3%) |
Nuclear staining evaluated using two different cut-offs from the literature.